Under this alliance, GSK will supply bulk vaccine and provide technology and expertise to enable Binnopharm to undertake the secondary manufacture, including filling and packaging of a number of GSK vaccines in accordance with international current Good Manufacturing Practice (cGMP) standards.
Binnopharm will be responsible for gaining approval of their facilities to allow supply of GSK cervical cancer, rotavirus and pneumococcal vaccines under Binnopharm’s trademark for the Russian public market.
GSK will book sales of the bulk vaccine supplied to Binnopharm through this alliance.
GSK Emerging Markets & Asia Pacific president Abbas Hussain said that this agreement is an example of the flexible approach we are taking to make vaccines more available in emerging markets through local partnerships.
Binnopharm general manager Maxim Uvarov said that the prompt implementation of this joint project between Binnopharm and GSK is a testament to the continued investment in the existing facilities and the quality of the Russian staff and management who have worked efficiently to create an international and innovative business partnership.